Last reviewed 2026-05-28 · How we verify

Oxybutynin ER

Oxybutynin ER is a Anticholinergic agent Small molecule drug developed by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. It is currently FDA-approved for Overactive bladder with symptoms of urge incontinence, urgency, and frequency, Neurogenic detrusor overactivity in patients with spinal cord injury or other neurological conditions. Also known as: Ditropan XL, Urotrol, Oxytrol.

Oxybutynin is an anticholinergic agent that blocks muscarinic acetylcholine receptors in the bladder smooth muscle, reducing involuntary contractions and increasing bladder capacity.

Oxybutynin ER is a small molecule that acts as a muscarinic acetylcholine receptor M3 antagonist. It is used to treat overactive bladder, a condition studied in various clinical trials.

At a glance

Mechanism of action

By antagonizing M3 muscarinic receptors on detrusor muscle, oxybutynin decreases the frequency and amplitude of bladder contractions. This anticholinergic action increases functional bladder capacity and reduces urinary urgency and incontinence episodes. The extended-release formulation provides sustained drug delivery over 24 hours, improving tolerability compared to immediate-release formulations.

Approved indications

• Overactive bladder with symptoms of urge incontinence, urgency, and frequency
• Neurogenic detrusor overactivity in patients with spinal cord injury or other neurological conditions

Common side effects

• Dry mouth
• Constipation
• Dizziness
• Somnolence
• Headache
• Blurred vision

Key clinical trials

• Oxybutynin ER to Promote Early Continence Recovery After Robotic Prostatectomy: A Randomized Controlled Trial (NA)
• The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled Trial (PHASE3)
• Fasting Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg (PHASE1)
• Food Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg (PHASE1)
• Fed Study of Oxybutynin Chloride Extended-release Tablets 10 mg and Ditropan XL® Tablets 10 mg (PHASE1)
• Efficacy and Safety of Oxybutynin Versus Paroxetine in Aromatase Inhibitor-induced Vasomotor Symptoms (PHASE3)
• Effects Of Detrol LA On Memory And Cognition In Elderly Population (PHASE4)
• Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Oxybutynin ER CI brief — competitive landscape report
• Oxybutynin ER updates RSS · CI watch RSS
• Pfizer's Upjohn has merged with Mylan to form Viatris Inc. portfolio CI

Frequently asked questions about Oxybutynin ER

Related

• Drug class: All Anticholinergic agent drugs
• Target: All drugs targeting Muscarinic acetylcholine receptors (M3)
• Manufacturer: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. — full pipeline
• Therapeutic area: All drugs in Urology / Neurology
• Indication: Drugs for Overactive bladder with symptoms of urge incontinence, urgency, and frequency
• Indication: Drugs for Neurogenic detrusor overactivity in patients with spinal cord injury or other neurological conditions
• Also known as: Ditropan XL, Urotrol, Oxytrol

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing